Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
COMMENTARY COMMENTARY:Korosho Must Explain Its "Primary Doctor" System Proposal in Detail
October 1, 2007
-
ARCHIVE R&D NEWS IN BRIEF
October 1, 2007
-
ARCHIVE Environment to Allow Both Work and Childcare Needed to Retain Female MRs
October 1, 2007
-
ARCHIVE Feasibility Studies for Joint Clinical Trials in Asia Increasing: CMIC
October 1, 2007
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 1, 2007
-
ARCHIVE Chuikyo Members Favor Changes in Comparator Drug Selection Rule
October 1, 2007
-
ARCHIVE JSMD Issues Official Statement on Risk of Suicide due to Antidepressants
October 1, 2007
-
ARCHIVE Novartis to Apply for Withdrawal of Depression as Indication for Ritalin
October 1, 2007
-
ARCHIVE Scheduled Replacement Therapy Better for Hemophiliacs: Bayer Yakuhin Seminar
October 1, 2007
-
ARCHIVE GENERICS NEWS IN BRIEF
October 1, 2007
-
ARCHIVE Appropriate Diagnosis and Treatment of Irritable Bowel Syndrome Needed: Seminar
October 1, 2007
-
ARCHIVE Interferon Treatment Should Be Spread by Sharing Know-how
October 1, 2007
-
ARCHIVE Chuikyo Recommends NHI Price Listing for 14 Products (9 APIs)
October 1, 2007
-
ARCHIVE Staff's Workload Must Be Reduced to Promote Clinical Trials at Univ. Hospitals: Mr Miura
October 1, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
October 1, 2007
-
ARCHIVE Pharmacoeconomics Essential for Assessing Drugs: Dr Aoki
October 1, 2007
-
ARCHIVE Boehringer Ingelheim Ties Up with Ablynx for Nanobody Therapeutics
September 24, 2007
-
ARCHIVE Takara Bio Licenses Anticancer Immunotherapy to Korean Company
September 24, 2007
-
ARCHIVE Nihon Medi-Physics, Nippon Kayaku to Handle Metastron of GE Healthcare
September 24, 2007
-
ARCHIVE Environment Assuring Rapid Supply of New Anticancer Drugs Needed
September 24, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…